CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print June 16, 2010
CA Cancer J Clin 2010; 60:222-243
doi: 10.3322/caac.20075
© 2010 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow All Versions of this Article:
caac.20075v1
60/4/222    most recent
Right arrow Submit a Comment to the editor
Right arrow Comments: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Comments are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cook, K. M.
Right arrow Articles by Figg, W. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cook, K. M.
Right arrow Articles by Figg, W. D.

Angiogenesis Inhibitors: Current Strategies and Future Prospects

Kristina M. Cook, DPhil1, and William D. Figg, PharmD2

1Molecular Pharmacology Section, Medical Oncology Branch and Affiliates, National Cancer Institute, National Institutes of Health, Bethesda, MD
2Molecular Pharmacology Section, Medical Oncology Branch and Affiliates, National Cancer Institute, National Institutes of Health, Bethesda, MD

Corresponding author: William D. Figg, PharmD, Molecular Pharmacology Section, Medical Oncology Branch and Af.liates, National Cancer Institute, National Institutes of Health, 10 Center Drive, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892; wdfigg{at}helix.nih.gov



DISCLOSURES: The authors reported no conflicts of interest.

Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (eg, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor), receptor tyrosine kinases, and transcription factors such as hypoxia inducible factor, as well as molecules involved in mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of antitumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.




Comments:

Read all Comments

Cancer pharmacogenomics potential to offer individualized cancer treatment by angiogenesis inhibitor
Xiaoying Lei, et al.
CA Online, 16 Jul 2010 [Full text]
Vasculogenic mimicry: an alternative vascularization mechanism beyond tumor angiogenesis
Yao-Qing Yu
CA Online, 21 Jul 2010 [Full text]
Target genes detection associated with angiogenesis inhibitors respond
Yuesheng Xia, et al.
CA Online, 23 Jul 2010 [Full text]
Notch signaling pathway inhibitors and tumor antiangiogenic therapy
Junchuan Lei, et al.
CA Online, 2 Aug 2010 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2010 by American Cancer Society.